ACS chemical neuroscience molecule spotlight on RG1678

Research output: Contribution to journalArticle

11 Scopus citations

Abstract

RG1678 is a glycine transporter-1 inhibitor currently in Phase III trials for the treatment of the negative symptoms of schizophrenia and is being developed by Roche (in combination with Chugai). Recent Phase II data shows that RG1678 is effective in reducing the negative symptoms when given in combination with second generation antipsychotics.

Original languageEnglish (US)
Pages (from-to)685-686
Number of pages2
JournalACS Chemical Neuroscience
Volume2
Issue number12
DOIs
Publication statusPublished - Dec 21 2011

    Fingerprint

Keywords

  • GlyT1
  • RG1678
  • Schizophrenia
  • glycine transporter-1 inhibitor
  • negative symptoms

ASJC Scopus subject areas

  • Biochemistry
  • Physiology
  • Cognitive Neuroscience
  • Cell Biology

Cite this